NHS could recoup cost of ineffective drugs
- Published: 04 June 2007 00:00
- Last Updated: 04 June 2007 12:18
The National Institute for Health and Clinical Excellence is recommending an innovative deal for an anti-cancer drug. It says patients with multiple myeloma who show a full or partial response to the drug Velcade should be kept on it and be funded by the NHS.
Those showing a minimal response or no response should be taken off it - with all drug costs refunded by the manufacturer, Janssen-Cilag.
